196 related articles for article (PubMed ID: 17329551)
1. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
Rizzi A; Gavioli EC; Marzola G; Spagnolo B; Zucchini S; Ciccocioppo R; Trapella C; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
[TBL] [Abstract][Full Text] [Related]
3. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
4. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
Liao YY; Jiang F; Chiou LC
Eur J Pharmacol; 2011 Apr; 657(1-3):84-8. PubMed ID: 21300055
[TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.
Gavioli EC; Vaughan CW; Marzola G; Guerrini R; Mitchell VA; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo' G
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):547-53. PubMed ID: 15197534
[TBL] [Abstract][Full Text] [Related]
10. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test.
Gavioli EC; Marzola G; Guerrini R; Bertorelli R; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo G
Eur J Neurosci; 2003 May; 17(9):1987-90. PubMed ID: 12752799
[TBL] [Abstract][Full Text] [Related]
11. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).
Zaratin PF; Petrone G; Sbacchi M; Garnier M; Fossati C; Petrillo P; Ronzoni S; Giardina GA; Scheideler MA
J Pharmacol Exp Ther; 2004 Feb; 308(2):454-61. PubMed ID: 14593080
[TBL] [Abstract][Full Text] [Related]
12. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
[TBL] [Abstract][Full Text] [Related]
13. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.
Rizzi A; Nazzaro C; Marzola GG; Zucchini S; Trapella C; Guerrini R; Zeilhofer HU; Regoli D; Calo' G
Pain; 2006 Sep; 124(1-2):100-8. PubMed ID: 16697109
[TBL] [Abstract][Full Text] [Related]
14. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
Rizzi A; Sukhtankar DD; Ding H; Hayashida K; Ruzza C; Guerrini R; Calò G; Ko MC
Br J Pharmacol; 2015 Jul; 172(14):3661-70. PubMed ID: 25828800
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
Rizzi A; Spagnolo B; Wainford RD; Fischetti C; Guerrini R; Marzola G; Baldisserotto A; Salvadori S; Regoli D; Kapusta DR; Calo G
Peptides; 2007 Jun; 28(6):1240-51. PubMed ID: 17532097
[TBL] [Abstract][Full Text] [Related]
16. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
Marti M; Mela F; Budri M; Volta M; Malfacini D; Molinari S; Zaveri NT; Ronzoni S; Petrillo P; Calò G; Morari M
Br J Pharmacol; 2013 Feb; 168(4):863-79. PubMed ID: 22994368
[TBL] [Abstract][Full Text] [Related]
17. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
[TBL] [Abstract][Full Text] [Related]
18. NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice.
Brunori G; Weger M; Schoch J; Targowska-Duda K; Barnes M; Borruto AM; Rorick-Kehn LM; Zaveri NT; Pintar JE; Ciccocioppo R; Toll L; Cippitelli A
Alcohol Clin Exp Res; 2019 Oct; 43(10):2167-2178. PubMed ID: 31386211
[TBL] [Abstract][Full Text] [Related]
19. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
20. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
